The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-163

Abnormal protein accumulation within motor neurons of the brain associates with the cause of ALS/MND. Inhibition of the mTOR signaling pathway slows disease progression in certain preclinical models of ALS/MND and is suggested to provide synergy with the ALS/MND standard-of-care drug, riluzole. An alternative mTOR inhibitor, rapamycin, is currently the subject of an ALS/MND clinical trial in humans investigating control of disease progression. Monepantel has a different structure to rapamycin and an apparently better safety profile.

This from classic.clinicaltrials.gov

So this gives me confidence that Monepantel is a new breed of mTOR inhibitor (that as you pointed out, crosses the BBB) and all the spruiking by MT of late isn’t just hype. He’d be very silly to be this confident publicly for less than ideal results to be released in a week or two.